When you need a common medication like metformin, ibuprofen, or amoxicillin, chances are you’re taking a generic version. These drugs work just like their brand-name counterparts but cost far less. But how long does it actually take for the FDA to approve them? The answer isn’t simple - it depends on the drug, the application, and whether the FDA has enough resources to review it quickly.
What the FDA Actually Reviews
The FDA doesn’t test generic drugs the same way it tests new ones. Brand-name drugs go through years of clinical trials to prove they’re safe and effective. Generics don’t need that. Instead, they must prove they’re bioequivalent - meaning they deliver the same amount of active ingredient into the bloodstream at the same rate as the original drug. This is done through lab tests and small human studies, not full-scale clinical trials.
The application used for this process is called an Abbreviated New Drug Application, or ANDA. The word “abbreviated” is key here. It means the FDA skips the lengthy safety and efficacy studies because the original drug already passed them. But that doesn’t mean the review is easy. The FDA still checks every detail: how the drug is made, how stable it is, whether the manufacturing site meets quality standards, and whether the final product matches the brand-name version in every measurable way.
Standard Review Timeline: Around 10 Months
Under the Generic Drug User Fee Amendments (GDUFA), the FDA sets performance goals for review times. For a standard ANDA, the target is 10 months from the date the application is accepted for review. That’s not from when you submit it - it’s from when the FDA confirms it’s complete enough to start evaluating. Before that, there’s a 60-day filing review to check for missing information. If the application is incomplete, the FDA sends a letter asking for more data. That resets the clock.
Real-world data from 2025 shows the FDA is getting better. The average approval time for standard generics dropped from 42.4 days in early 2024 to just 35.6 days by late 2025. That’s not a typo - those numbers are in days, not months. Why? Because the FDA now tracks how long it takes from the start of review to final approval, not the entire process from submission. The 10-month goal still stands for the full review cycle, but the actual evaluation phase is moving faster.
Why Some Approvals Take Much Longer
Not all generics are created equal. A simple tablet you swallow with water? That’s straightforward. But what about a nasal spray, an injectable suspension, or a patch that releases medicine slowly over days? Those are called complex generics. They’re harder to copy because the delivery system matters as much as the chemical. The FDA has to test not just whether the drug gets into the blood, but whether it gets there in the right way - at the right speed, in the right place.
For these complex products, review times can stretch to 18 months or more. One user on Reddit reported a 1,087-day approval timeline for a generic nasal spray. That’s almost three years. Meanwhile, another person got approval for a basic tablet in 278 days - less than nine months. The difference? Complexity. The FDA has dedicated teams for complex generics, and since 2023, they’ve cut approval times for these products by 22%. But even with those improvements, they’re still far slower than simple formulations.
Priority Review: Faster, But Not Guaranteed
If a generic drug is the first available version of a medication that’s in short supply, the FDA can give it priority review. This doesn’t mean a magic button gets pressed - it means the application gets bumped to the front of the line. The FDA doesn’t publish exact timeframes for priority generics, but industry insiders say they’re often approved in 6 to 8 months. Some have been approved in under 100 days.
The FDA prioritizes drugs that treat conditions like diabetes, heart disease, or epilepsy - especially when there’s only one manufacturer making them. In 2025, the agency approved first generics for epinephrine injections and doxycycline oral suspension because they were critical for public health. The goal? Prevent shortages. The FDA even has a new program called the Commissioner’s National Priority Voucher (CNPV) that could cut approval times from 10 months to just 1 to 2 months for the most urgent cases. This is still new, but early results show promise.
What Happens When the FDA Says “No”
Not every application gets approved on the first try. In fact, 42.3% of ANDAs received a complete response letter in Q2 2025 - up from 37.8% the year before. This isn’t a rejection. It’s a list of problems: missing data, unclear manufacturing details, or failure to prove bioequivalence. The company then has to fix those issues and resubmit. Each new round adds 3 to 6 months to the timeline.
Manufacturers say inconsistent feedback is one of the biggest frustrations. One regulatory manager at Teva told a forum that response letters sometimes ask for the same information twice. Others complain about delays in scheduling inspections of overseas manufacturing plants - a major bottleneck. The FDA is working on this, using AI to flag issues earlier and reducing the number of unnecessary requests. Still, multiple review cycles are common, especially for first-time applicants.
How the FDA Is Speeding Things Up
The FDA didn’t get faster by accident. It’s the result of several changes:
- GDUFA funding: Drug companies pay user fees - $138,400 per ANDA in 2025 - that go directly to hiring more reviewers and improving technology.
- AI tools: Internal pilot programs in 2024 cut review times for standard generics by 15.8% using AI to analyze data faster.
- Rolling submissions: Companies can now send parts of their application as they’re ready, instead of waiting to submit everything at once.
- Priority vouchers: The CNPV program targets the most urgent drugs, slashing review times to just 1-2 months.
These changes have helped. Between 2020 and 2024, median approval times dropped by 18.7%. The FDA’s goal by 2027 is to approve 90% of standard generics by their target date and 75% of priority ones. For simple drugs, they’re even aiming for a median approval time of just 20 days.
Who Benefits the Most?
Patients win when generics hit the market faster. In 2025, generics made up 90% of all prescriptions in the U.S. but only 23% of total drug spending. That’s how much money they save - an estimated $1.7 trillion over the last decade. The biggest manufacturers - Teva, Viatris, and Sandoz - have the shortest approval times because they’ve built strong relationships with the FDA. They use pre-submission meetings to clarify requirements before filing, reducing surprises later.
Small companies struggle more. Only 4.7% of ANDAs come from small businesses, and many don’t have the resources to handle multiple review cycles. Fee waivers exist, but they’re rare. The system favors those who know the rules.
What’s Next?
The FDA’s plan is clear: keep improving. By 2027, they want to approve most standard generics in under a month. That’s ambitious. Critics worry rushing approvals might mean missing quality issues. But the FDA says it’s using a risk-based approach - focusing more time on complex or high-demand drugs, not cutting corners.
One thing’s for sure: the clock is ticking faster than ever. If you’re waiting for a generic drug to become available, the wait is getting shorter - but it still depends on what kind of drug it is, how complete your application is, and whether the FDA thinks it’s worth prioritizing.
How long does it take the FDA to approve a generic drug?
The FDA targets a 10-month review time for standard generic drugs from the date the application is accepted. But the actual time varies widely. Simple tablet formulations can be approved in as little as 8 to 12 months total, while complex products like nasal sprays or injectables may take 18 months or longer. The FDA’s median approval time for standard generics dropped to 25 days in late 2025, meaning the actual evaluation phase is moving much faster than in the past.
What’s the difference between standard and priority review?
Standard review follows the 10-month timeline for most generic applications. Priority review is given to drugs that treat serious conditions or are in short supply. These get moved to the front of the line. While the FDA doesn’t publish exact timelines for priority generics, industry data suggests they’re often approved in 6 to 8 months - sometimes even under 100 days. The new Commissioner’s National Priority Voucher program aims to cut this further, to just 1 to 2 months for the most urgent cases.
Why do some generic drug approvals take years?
Complex formulations - like inhalers, injectables, or long-acting patches - are harder to copy because the delivery system affects how the drug works. The FDA must test not just the chemical, but how it’s delivered. Manufacturing sites overseas also add delays due to inspection scheduling. And if the application is incomplete or has errors, the FDA sends a complete response letter, which restarts the clock. Some applicants spend years fixing issues before approval.
Can the FDA approve a generic drug faster than 10 months?
Yes. Under the new Commissioner’s National Priority Voucher program, the FDA can approve the most critical generics in as little as 1 to 2 months. This applies to drugs with no competition or those in short supply. Even without the voucher, some applications are approved in 6 to 8 months if they’re high-quality and don’t require multiple review cycles. The FDA’s use of AI and rolling submissions has also helped cut review times.
What percentage of generic applications are approved on the first try?
As of Q2 2025, only about 57.7% of ANDAs were approved without a complete response letter. That means 42.3% received feedback requiring changes before approval. This rate has been rising slightly over the past year, indicating the FDA is being more thorough - not necessarily stricter. Companies with experience submitting applications have much higher first-time approval rates, often above 70%.
